# A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Source: https://onco.cc/trials/nct05235516/  
OnCo record `nct05235516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab and Cisplatin in cervical cancer, run by Akeso, active and no longer recruiting.

## Summary

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer is a phase 3 interventional study registered as NCT05235516 by Akeso, with 636 participants enrolled, started 2022-06-21 and due to reach its primary completion in 2026-05. Interventions recorded: AK104, EBRT, BT, cisplatin and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05235516
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Sponsor: Akeso
- Enrolled: 636

## Sources

- ClinicalTrials.gov NCT05235516: https://clinicaltrials.gov/study/NCT05235516

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05235516.json